Multiplex Biomarker Imaging Global Market Report 2024

The multiplex biomarker imaging market size has grown rapidly in recent years. It will grow from $0.44 billion in 2023 to $0.49 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to several factors, including the high incidence of cancer, the demand for precise diagnostic tools, the increasing prevalence of chronic diseases, the aging population, and the shift towards personalized medicine.

The multiplex biomarker imaging market size is expected to see rapid growth in the next few years. It will grow to $0.74 billion in 2028 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to an increasing emphasis on personalized medicine, heightened research and development activities, a rise in clinical trials, the necessity for high-throughput screening methods in drug discovery, and supportive regulatory frameworks and guidelines. Major trends expected during this period include technological advancements, innovations in imaging technologies, advances in digital pathology, developments in data analysis and imaging software, and the integration of AI and machine learning with imaging technologies.

The increasing prevalence of chronic diseases is expected to drive the growth of the multiplex biomarker imaging market in the coming years. Chronic diseases are enduring health conditions that persist or recur over time, often with complex origins, multiple risk factors, and extended latency periods. The rising prevalence of chronic diseases can be attributed to various factors, including the rapid aging of populations, improved disease detection methods, better disease treatment and management, and changes in lifestyle and environmental risk factors. Multiplex biomarker imaging plays a vital role in managing chronic diseases by enabling comprehensive analysis and characterization of disease progression and response to treatment. For instance, a report published by the National Institutes of Health (NIH) in January 2023 projected a 99.5% increase in the number of individuals aged 50 and older with at least one chronic illness, from 71.52 million in 2020 to 142.66 million in 2050. Hence, the growing prevalence of chronic diseases is fueling the expansion of the multiplex biomarker imaging market.

Major players in the multiplex biomarker imaging market are focusing on offering innovative solutions, such as automated slide loaders, to deliver advanced imaging capabilities and enhance customer experience. Automated slide loaders streamline sample handling, reducing manual effort and improving throughput, which is crucial for conducting high-volume multiplex biomarker imaging experiments. For example, Standard BioTools Inc., a US-based provider of analytical systems and instruments, introduced the Hyperion XTi Imaging System in April 2024, featuring a new high-throughput multiplexed whole slide with added automation and flexibility. This system offers three modes for rapid analysis - preview, tissue, and cell modes - enabling researchers to quickly visualize tissue heterogeneity and conduct in-depth analysis. The novel whole slide imaging approach using imaging mass cytometry (IMC) provides up to 10 times higher throughput compared to cyclic immunofluorescent imaging. Additionally, the inclusion of an automated slide loader streamlines high-throughput imaging, reducing manual effort and ensuring standardization. These innovations aim to expedite breakthroughs in spatial proteomics, providing reliable insights into health and disease.

In March 2024, Calyx, a UK-based provider of medical imaging services, merged with Invicro to create a global leader in medical imaging and software solutions. This merger brings together expertise in medical imaging and software to offer enhanced support to customers in the biopharma industry, ranging from large pharmaceutical companies to specialized biotech firms. The merger between Calyx and Invicro, a US-based next-generation quantitative imaging biomarker company, creates a differentiated industry leader and addresses growing customer needs for comprehensive support.

Major companies operating in the multiplex biomarker imaging market are Merck KGaA, Thermo Fisher Scientific Inc., Danaher corporation, Becton Dickinson and Company (BD), Carl Zeiss AG, Illumina Inc, PerkinElmer Inc., Bio-Rad Laboratories Inc, Bruker Corporation, Bio-Techne Corporation, Leica Biosystems Nussloch GmbH, Abcam Plc, Meso Scale Diagnostics LLC, Fluidigm Corporation, NanoString Technologies, Quanterix Corporation, Akoya Biosciences, Enzo Biochem Inc, Cisbio Bioassays, Flagship Biosciences, Aushon BioSystems Ltd, Ionpath Inc., Biosims Technologies.

North America was the largest region in the multiplex biomarker imaging market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiplex biomarker imaging market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the multiplex biomarker imaging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Multiplex biomarker imaging is a technique that enables the simultaneous detection and analysis of multiple biomarkers within a single sample. This approach allows for the visualization of complex biological processes and molecular profiles. Advanced imaging technologies are used to map the spatial distribution of biomarkers within tissues, providing detailed insights into cellular interactions and microenvironments.

The main components of multiplex biomarker imaging include instruments, software, and services. Instruments are tools or devices used for specific scientific tasks or for making measurements such as speed, height, or sound. Imaging techniques used in this context include immuno fluorescence (IF) assay, tissue microarray (TMA) assay, immunohistochemistry (IHC) assay, fluorescent in situ hybridization (FISH) assay, and toponome imaging system (TIS). These techniques find applications in areas such as drug safety, oncology studies, and genetic characterization studies. End users of multiplex biomarker imaging include research institutes (government and private), clinical labs, pharmaceutical companies, and biotechnology firms.

The multiplex biomarker imaging market research report is one of a series of new reports that provides multiplex biomarker imaging market statistics, including the multiplex biomarker imaging industry global market size, regional shares, competitors with the multiplex biomarker imaging market share, detailed multiplex biomarker imaging market segments, market trends, and opportunities, and any further data you may need to thrive in the multiplex biomarker imaging industry. These multiplex biomarker imaging market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The multiplex biomarker imaging market consists of revenues earned by entities by providing services such as imaging and analysis services, pathology services, and clinical and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The multiplex biomarker imaging market also includes sales of imaging instruments, reagents and kits, software, and analysis tools that are used in providing multiplex biomarker imaging services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.